These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39228686)

  • 1. Sample size considerations for single-arm clinical trials with time-to-event endpoint using the gamma distribution.
    Dai J; He J; Phadnis MA
    Contemp Clin Trials Commun; 2024 Oct; 41():101344. PubMed ID: 39228686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing accuracy of Weibull shape parameter estimate from historical studies for subsequent sample size calculation in clinical trials with time-to-event outcome.
    Phadnis MA; Sharma P; Thewarapperuma N; Chalise P
    Contemp Clin Trials Commun; 2020 Mar; 17():100548. PubMed ID: 32154431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
    Phadnis MA; Mayo MS
    Biom J; 2021 Oct; 63(7):1406-1433. PubMed ID: 34272897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size calculation for small sample single-arm trials for time-to-event data: Logrank test with normal approximation or test statistic based on exact chi-square distribution?
    Phadnis MA
    Contemp Clin Trials Commun; 2019 Sep; 15():100360. PubMed ID: 31080909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
    Waleed M; He J; Phadnis MA
    J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
    Waleed M; He J; Phadnis MA
    Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution.
    Jiang Z; Wang L; Li C; Xia J; Jia H
    PLoS One; 2012; 7(9):e44013. PubMed ID: 22957040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Power and sample size for randomized phase III survival trials under the Weibull model.
    Wu J
    J Biopharm Stat; 2015; 25(1):16-28. PubMed ID: 24895942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical considerations of designs for single-arm proof-of-concept oncology trial with time-to-event endpoint.
    Zhou H; Sun L; Wang M
    Contemp Clin Trials; 2023 Jun; 129():107200. PubMed ID: 37068588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconsideration of sample size and power calculation for overall survival in cancer clinical trials.
    Jung I; Ko HJ; Rha SY; Nam CM
    Contemp Clin Trials Commun; 2018 Dec; 12():90-91. PubMed ID: 30302417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size determination for time-to-event endpoints in randomized selection trials with generalized exponential distribution.
    Akbar MH; Ali S; Shah I; Alqifari HN
    Heliyon; 2024 Mar; 10(5):e27013. PubMed ID: 38455536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-arm Phase II cancer survival trial designs.
    Wu J
    J Biopharm Stat; 2016; 26(4):644-56. PubMed ID: 26098141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.
    Beca JM; Chan KKW; Naimark DMJ; Pechlivanoglou P
    BMC Med Res Methodol; 2021 Dec; 21(1):282. PubMed ID: 34922454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Power and sample size for survival analysis under the Weibull distribution when the whole lifespan is of interest.
    Heo M; Faith MS; Allison DB
    Mech Ageing Dev; 1998 May; 102(1):45-53. PubMed ID: 9663791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint.
    Qing Y; Thall PF; Yuan Y
    Pharm Stat; 2023 Jan; 22(1):34-44. PubMed ID: 35851545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model.
    Wu J
    Stat Biopharm Res; 2017; 9(1):25-34. PubMed ID: 28966721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample Size Reestimation in Stochastic Curtailment Tests With Time-to-Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters.
    Sharma P; Phadnis MA
    Pharm Stat; 2024 Aug; ():. PubMed ID: 39155271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
    Cotterill A; Whitehead J
    Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.